Shared decision making underpins good health care

17 June 2021 - Shared decision making between service users and health care professionals is an integral part of health care, ...

Read more →

How the patient voice is becoming vital for drug approval

14 June 2021 - Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a ...

Read more →

Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients

14 June 2021 - Bristol Myers Squibb’s immunotherapy combination Opdivo plus Yervoy has been recommended by NICE for the treatment ...

Read more →

NICE to reassess Kyowa Kirin’s Poteligeo

14 June 2021 - NICE will reassess Kyowa Kirin’s rare blood cancer treatment Poteligeo after upholding an appeal launched by ...

Read more →

Astellas’ Xtandi bags NICE approval in prostate cancer

10 June 2021 - Astellas’ oral treatment Xtandi has received approval from NICE for the treatment of metastatic hormone-sensitive prostate ...

Read more →

NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis

10 June 2021 - Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to ...

Read more →

Integrating early economic evaluation into target product profile development for medical tests: advantages and potential applications

7 June 2021 - Target product profiles outline the characteristics that new health care technologies require to address an unmet clinical ...

Read more →

NICE recommends Tecentriq for first-line NSCLC

7 June 2021 - NICE has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer. ...

Read more →

NICE publishes appraisal consultation document for medicine for excessive daytime sleepiness

3 June 2021 - The Department of Health and Social Care has asked the NICE to produce guidance on using pitolisant ...

Read more →

NICE turns down GSK's IV Benlysta for systemic lupus

4 June 2021 - NICE has rejected NHS funding for an intravenous formulation of GlaxoSmithKline's Benlysta (belimumab) as an add-on ...

Read more →

NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient group

2 June 2021 - NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in ...

Read more →

NICE draft guidance does not recommend risdiplam for treating spinal muscular atrophy

2 June 2021 - NICE has today published draft guidance for public consultation which does not recommend risdiplam (Evrysdi, Roche) for ...

Read more →

Examining the impact of different country processes for appraising rare disease treatments: a case study analysis

31 May 2021 - Conventional appraisal and reimbursement processes are being challenged by the increasing number of rare disease treatments with ...

Read more →

NICE green lights Tremfya to treat active psoriatic arthritis

28 May 2021 - Janssen’s IL-23 inhibitor Tremfya has been accepted for NHS use by the UK’s NICE for the ...

Read more →

Colchester baby's parents feel 'abandoned' over £1.7 million drug

25 May 2021 - A baby with a fatal genetic condition has been "abandoned" in a "race against time" for ...

Read more →